| Literature DB >> 28318627 |
Shinji Tanaka1, Tetsuhiro Tanaka1, Takahisa Kawakami1, Hideki Takano2, Mai Sugahara1, Hisako Saito1, Yoshiki Higashijima1, Junna Yamaguchi1, Reiko Inagi3, Masaomi Nangaku4.
Abstract
Vascular adhesion protein-1 (VAP-1) is a unique molecule since it acts as an adhesion molecule as well as an ectoenzyme catalyzing oxidative deamination of primary amines and generates hydrogen peroxide in the extracellular space. While VAP-1 is implicated in various inflammatory diseases, its role in acute kidney injury is less characterized. Here we studied VAP-1 expression in the kidney and the effect of its inhibition in a rat model of renal ischemia/reperfusion injury. VAP-1 was predominantly expressed in pericytes, which released enzymatically active enzyme. In vivo, a specific VAP-1 inhibitor, RTU-1096, significantly ameliorated rat renal ischemia/reperfusion injury and decreased neutrophil infiltration measured 12 hours after injury without altering macrophage or T lymphocyte populations. The protective effect of VAP-1 inhibition was lost in neutrophil-depleted rats, suggesting its inhibition ameliorated renal ischemia/reperfusion injury by suppressing neutrophil infiltration. To investigate whether hydrogen peroxide generated by VAP-1 enzyme reaction enhances neutrophil infiltration, we conducted an under-agarose migration assay with purified human neutrophils. Recombinant human VAP-1 significantly induced neutrophil migration, which was almost completely inhibited by RTU-1096 or catalase. Thus, VAP-1 plays a critical role in the pathophysiology of renal ischemia/reperfusion injury by enhancement of neutrophil infiltration generating a local hydrogen peroxide gradient. Hence, VAP-1 inhibition may be a novel therapy in ischemic acute kidney injury.Entities:
Keywords: acute kidney injury; inflammation; ischemia reperfusion
Mesh:
Substances:
Year: 2017 PMID: 28318627 DOI: 10.1016/j.kint.2017.01.014
Source DB: PubMed Journal: Kidney Int ISSN: 0085-2538 Impact factor: 10.612